Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Active Ulcerative Colitis (ACT 2)
NCT00096655Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2002
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of infliximab in ulcerative colitis (UC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients with clinical response at 8 weeks. Started May 2002; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00096655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096655.